Mr. Van Hooland is Founding Partner at Droia. Previously, he was the Managing Partner from the foundation of Droia in 2012 through to 2018. Mr. Van Hooland is responsible for building the Droia network, developing investment opportunities and managing portfolio investments.
He acted as interim CEO for two of Droia’s portfolio companies, including at the creation of former portfolio company Tusk Therapeutics, which was acquired by Roche in 2018. Mr. Van Hooland is a Director on the Boards at Bioncotech, Cristal Therapeutics and Convert Pharmaceuticals.
He graduated as an engineer from the University of Ghent and has an MBA from INSEAD. He worked as a strategy consultant at BCG in Paris and Brussels, and has since been owner, manager and director of several companies before co-founding Droia. Mr. Van Hooland is a member of the Board of Directors of Gimv, a Euronext listed private equity and venture capital investor. He is also on the Advisory Boards of the Hermes Fund, which has succeeded IWT, the Flemish agency for innovation through science and technology, where he was a Director and of PMV, the investment company of the Flemish government. GIMV, IWT and PMV have been instrumental in the development of the Belgian biotech ecosystem.